Agarwal Arjun sold $846K of ORKA
Agarwal Arjun (Senior Vice President, Finance) sold 9,999 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $84.63 ($83.07–$85.63, $0.85M total) across 4 trades on 2026-07-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price range, and post-transaction holdings by a finance officer under a 10b5-1 plan. This can influence short-term sentiment but does not provide new fundamentals.
Market read
Traders may monitor ORKA for sentiment effects from insider activity, but the 10b5-1 framing reduces interpretive weight.
What to watch
The filing does not disclose reasons for the sale, and it does not indicate whether other insiders are buying or whether the company has concurrent catalysts (trials, approvals, financing).
Background
The article is a SEC Form 4 insider transaction disclosure for Oruka Therapeutics, Inc. (ORKA).
Ticker impact
Oruka Therapeutics (ORKA) disclosed an officer open-market sale by SVP Finance Agarwal Arjun of 9,999 shares for about $846K under a 10b5-1 plan.
Low near-term impact; any reaction is likely limited to sentiment and liquidity rather than fundamentals.
The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan, and it provides no new company performance, guidance, or deal information.
Market effects
Minimal. Insider selling in a single biotech does not, by itself, reset sector expectations.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.
Key entities
- issuerOruka Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure (ORKA).
- insiderAgarwal Arjun
Senior Vice President, Finance who sold 9,999 shares on 2026-07-13 under a 10b5-1 plan.
